Abstract: The present invention discloses an extracellular matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid.
Abstract: A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i) to iii): i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-? (TGF-?) inhibitor.
Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
July 19, 2022
Assignees:
NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATION
Abstract: Described herein are methods, compositions, and kits for forming engineered in vitro biomimetic, three-dimensional, tubular organoid structures by directed differentiation of human pluripotent stem cells within tubular channels formed in a hydrogel.
Type:
Grant
Filed:
October 16, 2019
Date of Patent:
July 19, 2022
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Randolph Scott Ashton, Carlos Ruben Marti-Figueroa
Abstract: The invention generally relates to a microfluidic platforms or “chips” for testing and understanding cancer, and, more specifically, for understanding the factors that contribute to cancer invading tissues and causing metastases. Tumor cells are grown on microfluidic devices with other non-cancerous tissues under conditions that simulate tumor invasion. The interaction with immune cells can be tested to inhibit this activity by linking a cancer chip to a lymph chip.
Type:
Grant
Filed:
March 30, 2017
Date of Patent:
June 28, 2022
Assignee:
EMULATE, INC.
Inventors:
Geraldine A Hamilton, Norman Wen, Catherine Karalis, Antonio Varone, Daniel Levner, Riccardo Barrile
Abstract: The present invention provides tissue scaffolds, methods of generating such scaffolds, and methods of use of such scaffolds to generate aligned and functional neural tissues for use in methods including regenerative medicine, wound repair and transplantation.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
June 21, 2022
Assignee:
THE TRUSTEES OF PRINCETON UNIVERSITY
Inventors:
Jeffrey Schwartz, Jean E. Schwarzbauer, Casey M. Jones, Patrick E. Donnelly, Stephen B. Bandini, Shivani Singh
Abstract: The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.
Type:
Grant
Filed:
April 2, 2018
Date of Patent:
May 31, 2022
Assignees:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Abstract: An implantable therapy delivery device that includes a porous pouch and a cell encapsulation device configured to fit inside the porous pouch. The porous pouch may include a bio-absorbable material and/or a vascularization promotor, and the porous pouch may be packaged separately from the cell encapsulation device.
Abstract: A particulate lyophilized platelet lysate composition suitable for use as a cell culture medium can include growth factors, cytokines, and chemokines released from lysis of source platelets, wherein cellular debris from the source platelets is removed (partially or fully) by filtration. The growth factors, cytokines, and chemokines are lyophilized to form a particulate lyophilized platelet lysate composition.
Abstract: The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.
Type:
Grant
Filed:
March 26, 2021
Date of Patent:
May 10, 2022
Assignees:
The Trustees of the University of Pennsylvania, Massachusetts Institute of Technology
Inventors:
Christopher S. Chen, Jan D. Baranski, Ritika Chaturvedi, Michael T. Yang, Kelly R. Stevens, Sangeeta N. Bhatia
Abstract: A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.
Type:
Grant
Filed:
February 6, 2019
Date of Patent:
May 10, 2022
Assignee:
Vivex Biologies Group, Inc.
Inventors:
Harry Thomas Temple, Timothy Ganey, Stephanie Gonzalez, Tracy Scott Anderson, Shabnam Namin
Abstract: The present application relates to biomimetic three-dimensional (3D) scaffolds, constructs and methods of making the same. The three-dimensional scaffold can include a sacrificial internal cast and a durable external scaffold material, wherein the durable external scaffold material comprises a biocompatible material which completely surrounds the sacrificial internal cast and wherein the sacrificial internal cast be removed to yield a branching 3D network of hollow, vessel-like tubes that substantially mimics a native tissue or organ.
Type:
Grant
Filed:
July 21, 2016
Date of Patent:
April 19, 2022
Assignee:
Wake Forest University Health Sciences
Inventors:
James Yoo, In Kap Ko, Jennifer Huling, Anthony Atala
Abstract: This invention relates to brown adipose tissue (BAT) progenitor cells and methods for isolating BAT progenitor cells from skeletal muscle. BAT progenitor cell surface markers and medium and agents for inducing cell differentiation into brown adipocytes are also provided. In some embodiments, the BAT progenitor cell expresses a first cell surface marker associated with endothelial cells, the first cell surface marker being detectable in an antibody based assay using a first antibody. In addition, the BAT progenitor cell can be substantially free of a second cell surface marker associated with endothelial cells, the second cell surface marker being substantially undetectable in said antibody based assay using a second antibody. The BAT progenitor cell can also be substantially free of additional cell surface markers.
Type:
Grant
Filed:
May 13, 2019
Date of Patent:
April 12, 2022
Assignee:
ENERGESIS PHARMACEUTICALS, INC.
Inventors:
Olivier D. Boss, Mihaela Crisan, Jean-Paul Giacobino
Abstract: Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
March 29, 2022
Assignee:
University of Kansas
Inventors:
Hiroshi Nishimune, Richard Barohn, Buddhadeb Dawn, Yomna Badawi, James W. Mitchell, Rupal Soder
Abstract: The present invention relates to drug discovery and development. More specifically, the present invention provides methods and composition useful for screening anti-cancer agents. In a specific embodiment, a method for screening candidate anti-cancer agents comprises the steps of (a) contacting a monolayer of reversible spheroid cancer cells with a candidate anti-cancer agent; and (b) measuring the response of the reversible spheroid cancer cells to the candidate anti-cancer agent.
Abstract: A system for washing red blood cells, comprising a separator configured to separate a quantity of blood into concentrated red blood cells having a hematocrit of at least 60% and a volume of 150-250 mL, and a supernatant component. The system comprises a flow controller configured to remove the supernatant component to provide an initial red blood cell concentrate; combine 50-500 mL of an additive solution with the red blood cell concentrate to provide an intermediate red blood cell product intended for storage for 42 days or less, wherein the intermediate red blood cell product at the end of storage has an osmolarity value between 202-479 mOsm/L; and wash the intermediate red blood cell product comprising the osmolarity value between 202-479 mOsm/L with a washing solution having an osmolarity value higher than that of the intermediate red blood cell product comprising the osmolarity value between 202-479 mOsm/L.
Abstract: The present disclosure relates to a subfractionation culturing method of a stem cell and proliferation method of a monoclonal stem cell obtained using the same. According to the subfractionation culturing method of stem cells and the proliferation thereof of the exemplary embodiments of the present disclosure, it is advantage that monoclonal stem cells may be quickly obtained without contamination, and desired monoclonal stem cells may be largely obtained in a short time through the rapid proliferation, thereby being used for the preparation of stem cell-therapeutic agents.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
February 15, 2022
Assignee:
SCM LIFESCIENCE CO., LTD.
Inventors:
Sun Uk Song, Si Na Kim, Yun Kyoung Cho, Dong Sik Ham
Abstract: The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.
Abstract: A wound or tissue healing composition and related treatment methods are provided. The wound or tissue healing composition includes an effective amount of a platelet-rich plasma aseptically recovered from umbilical cord and an effective amount of a human birth tissue material composition.
Abstract: Methods for treating degenerative disc disease by administering a human birth tissue material composition are provided. The method includes the step of administering a human birth tissue material composition onto or into at least one intervertebral disc or intervertebral space in need of treatment.